Relmada Therapeutics Inc., a NYC-based clinical-stage company developing novel therapies for the treatment of chronic pain, closed an $8m Series A financing.
The company intends to use the funds to to continue the development of its product pipeline and for general corporate activities.
Led by Sergio Traversa, CEO, Relmada is currently developing several drug candidates including:
– LevoCap ER, its abuse resistant, once–a-day sustained release dosage form of the opioid analgesic levorphanol, to enter Phase III of development;
– d-methadone, the NDMA receptor antagonist for diabetic painful neuropathy (DPN) to enter Phase IIb;
– BuCap, its oral dosage form of the opioid analgesic buprenorphine to start the pilot PK studies; and
– MepiGel, its FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine to start the pilot PK studies.